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Available online 10 March 2016Short-chain acyl-coA dehydrogenase deﬁciency (SCADD) is an autosomal recessive inborn error of mitochondrial
fatty acid oxidation caused by ACADS gene alterations. SCADD is a heterogeneous condition, sometimes considered
to be solely a biochemical condition given that it has been associatedwith variable clinical phenotypes ranging from
no symptoms or signs to metabolic decompensation occurring early in life.
A reason for this variability is due to SCAD alterations, such as the common p.Gly209Ser, that confer a disease
susceptibility state but require a complex multifactorial/polygenic condition to manifest clinically.
Our study focuses on 12 SCADD patients carrying 11 new ACADS variants, with the purpose of deﬁning genotype–
phenotype correlations based on clinical data, metabolite evaluation, molecular analyses, and in silico functional
analyses.
Interestingly, we identiﬁed a synonymous variant, c.765GNT (p.Gly255Gly) that inﬂuencesACADSmRNA splicing
accuracy.mRNAcharacterisationdemonstrated that this variant leads to an aberrant splicing product, harbouring
a premature stop codon.
Molecular analysis and in silico tools are able to characterise ACADS variants, identifying the severemutations and
consequently indicating which patients could beneﬁt from a long term follow- up. We also emphasise that synon-
ymous mutations can be relevant features and potentially associated with SCADD.






Short-chain acyl-CoA dehydrogenase (SCAD) deﬁciency (SCADD,
MIM 201470) is an autosomal recessive inborn error of mitochondrial
fatty acid oxidationwith highly variable clinical, biochemical and geneticogenase; SCADD, Short-chain
itine; EMA, ethylmalonic acid;
ectrometry; ACADS, Acyl CoA-
aboratory, Paediatric Neurology
yer Children's Hospital, Viale
. This is an open access article undercharacteristics [1]. SCADD is one of the most common inborn errors of
metabolism since it is estimated to affect approximately 1 in 35,000 to
50,000 newborns [1–2].
The characteristic manifestations of SCAD (MIM 606885) deﬁciency
include hypoglycaemia, weakness hypotonia and lethargy [3]
Biochemically, SCADD is associated with the accumulation of
butyrylcarnitine (C4-C), butyrylglycine, ethylmalonic acid (EMA), and
methylsuccinic acid in blood, urine and cells [4]. Blood C4-C and urinary
EMA are generally elevated and thus are currently used as biochemical
markers of the disease [1].
SCAD is a ﬂavoprotein consisting of four subunits, each of them con-
taining one molecule of the ﬂavin adenine dinucleotide cofactor (FAD).
FAD binding is important for the catalytic activity of ﬂavoproteins, as
well as their folding, assembly, and/or stability [5–6].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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developmental delay, epilepsy, behavioural disorders, hypoglycaemia,
and hypotonia.
Newborn screening (NBS) using tandemmass spectrometry (LC–MS/
MS) has led to the identiﬁcation of an increasing number of newborns
with altered biochemical markers suggesting SCADD. However, in con-
trast to infants inwhom clinical manifestations are a cause of referral, in-
fants brought to medical attention by NBS programmes could remain
largely asymptomatic [1,7].
The diagnosis of SCADD is usually conﬁrmed by molecular analysis.
The ACADS gene (MIM #606885), encoding SCAD, spans approximately
14.2 kb and consists of ten exons. To date, more than 60 inactivating
mutations have been reported in the ACADS gene, two of which, the
c.511CNT (p.Arg171Trp) and c.625GNA (p.Gly209Ser), are polymorphic
and generally referred to as gene variants. These two variants have not
been directly associated with SCADD although they were reported to
confer disease susceptibility when co-occurring with as yet undeter-
mined environmental or genetic factors [8–9]. Assuming that these
ACADS variants result in proteinmisfolding [10], riboﬂavin (the precursor
of FAD) therapymight be efﬁcacious. However, riboﬂavin responsiveness
in individualswith the c.625GNA (p.Gly209Ser) variant at a homozygous
state, was detected only in combination with an initial low FAD status
observed in patients' blood samples [11].
The purpose of this study is to increase the knowledge on the clinical
relevance of SCADD. We focus on 12 cases of SCADD exhibiting a new
genotype and report their clinical, biochemical and molecular data. We
detected 11 newmutations in the ACADS gene including the ﬁrst synon-
ymous (silent)mutation in a SCADDdisease causing allele.We evaluated
the pathogenic role of thenewmissense variants identiﬁed using in silico
predictions and performed RT-PCR analysis to study the effects of the
synonymous variant.2. Materials and methods
2.1. Clinical and biochemical analysis
This studywas carried out on 12 patients from11 unrelated families.
Clinical features, the EMA and C4-C values and ACADS gene molecu-
lar analyses are reported in Table 1.Table 1
Genotype, biochemical values and clinical features of the here reported 12 SCADD patients.
Patient ACADS gene Allele 1 ACADS gene Allele 2 Age at diagnosis Et
1 c. 842GNC p.Gly281Ala
c.625GNA p.Gly209Ser
c.625GNA p.Gly209Ser 5 y Ita
2 c.869CNG p.Ala290Gly
c.625GNA p.Gly209Ser
c.625GNA p.Gly209Ser 26 d Ita






5 c.1130CNT p.Pro377Leu c.625GNA p.Gly209Ser 17 y Ita
6 c.700CNT p.Arg234Trp c.625GNA p.Gly209Ser 9 d M
7 c.1157GNA p.Arg386His
c.625GNA p.Gly209Ser
c.625G N A p.Gly209Ser 8 d Ro
8 c.814CNT p.Arg272Cys c.814CNT p.Arg272Cys 16 d M
9 c.814CNT p.Arg272Cys c.814CNT p.Arg272Cys 8 d M
10 c.66GNA p.W22* c.625GNA p.Gly209Ser 8 d Pa
11 c.700CNT p.Arg234Trp c.700CNT p.Arg234Trp 14 d Ita
12 c.531 GNA p.Trp171* c.765GNT p.Gly255Gly 9 d Ita
– not performed: they were born before NBS programmes were established in our country; n.
Patients 8 and 9 are brothers.According to ethical guidelines, all cell and nucleic acid samples
were obtained for analysis and storage after patients' (and/or parental)
written informed consent, using a form approved by the local Ethics
Committee.
Quantitative assay of acylcarnitine was performed by tandem mass
spectrometry (LC/MS/MS) using an ABiSciex API 4000 triple-quadruple
mass spectrometer equipped with a TurboIonSpray source (ABiSciex,
Toronto, Canada) as previously reported [12].
2.2. Analysis of genomic DNA
Genomic DNA was isolated from peripheral blood lymphocytes or
cultured ﬁbroblasts, or both.
Ampliﬁcation of genomic fragments was performed on 200 ng of
genomic DNA; PCR conditions for all the ACADS exons included dena-
turation at 94 °C for 4 min, 30 cycles at 94 °C for 30 s, 63 °C for 30 s,
72 °C for 2 min, and a ﬁnal extension cycle at 72 °C for 10 min.
PCR products were visualised on a 2% agarose gel and puriﬁed using
Nucleospin Extract II extraction kit (Macherey-Nagel, Düren, Germany).
About 100 ng of puriﬁed DNA was analysed for mutation detection by
nucleotide sequencing on an ABI PRISM 3130 genetic analyser using
BigDye terminator chemicals (Life Technologies Italia, Monza, Italy).
2.3. Cell culture
T lymphocyteswere cultured in RPMImediumadded by foetal bovine
serum (heat inactivated for 30 min at 56 °C), interleukin 2 (800 μ/ml),
phytohemagglutinin (2.5 μg/ml) and antibiotics.
2.4. mRNA analyses
Total RNA was isolated from T lymphocytes cells by using the
RNeasy mini kit (Qiagen, Hilden, Germany). RNA integrity and concen-
tration were checked by 1% agarose gel and Nanodrop® ND-1000
Spectrophotometer (Nanodrop technologies, Wilmington, USA).
Total RNA (200 ng) was reverse transcribed with random hexamers
by using TaqMan Reverse Transcriptase kit (Applied Biosystems by
Life Technologies, Carlsbad, CA, USA) according to the manufacturer's
instructions.hnic origin C4-C μmol/L
(DBS) (n.v b 1)
EMA mmol/mol
creatinine (n.v. b 7)
Clinical symptoms




lian n.a 42 None
ilippine 1.05 154 Mild hypotonia, mild
hypertransaminasaemia
oroccan 4 182 none
lian – 14 Pervasive developmental
disorder, stereotypies,
dysmorphic features
oroccan 1.59 33 None
manian 1 28 None
oroccan 1.87 187 Mild hypotonia
oroccan 1.80 96 Mild hypotonia
kistani 1.13 36 None
lian 2.25 220 Mild hypotonia
lian 1.98 129 None
a. not available; y = years; d = days; n.v = normal values. The new variants are bolded.
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as template and primers RNA3F (5′-GTCATCATGAGTGTCAACAAC-3′) and
RNA8R (3′-CTTGATGAAAGGCTTCTTGTTA-5′) that anneal the ACADS
exons 3 and 8, respectively. PCR reactions were prepared in 25 μl of
ﬁnal volume in a reaction mixture containing 1× PCR buffer, 1.5 mM
MgCl2, 250 μM each dNTP, 15 pmol of each primer, and 1 U of Taq DNA
polymerase (Applied Biosystems by Life Technologies, Carlsbad, CA,
USA). After a primary denaturation for 5 min at 95 °C, ampliﬁcation
was carried out for 30 cycles of 30 s at 95 °C, 30 s at 56 °C and 2 min at
72 °C, with a ﬁnal extension of 7 min at 72 °C.
Splicing predictions performed by Alamut® software (http://www.
interactive-biosoftware.com/alamut.html), based on 5 different algo-
rithms (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, Human
Splicing Finder), were used to assume the role of the c.765GNT genetic
variation on the ACADS translation.
2.5. Screening of new mutations and in silico analyses
The 1000 Genomes project database (http://www.1000genomes.
org/), including all human genetic variations from the dbSNP short
genetic variations database (http://www.ncbi.nlm.nih.gov/omim)
and the ExAC Browser of the Exome Aggregation Consortium, which
provides a data set spanning over 60,000 unrelated individuals
(http://exac.broadinstitute.org), were used to evaluate the polymorphic
status of the identiﬁed genetic alterations. The frequency of the newly
identiﬁedmissense variants in the Italian populationwas also evaluated
by sequencing the ACADS gene in 100 healthy controls DNAs.
2.6. In silico analysis and tridimensional modelling of new missense
mutations onto the SCAD protein
The 3D SCAD structure and chemical bonds were examined in UCSF
Chimera (http://www.cgl.ucsf.edu/chimera/)(version 1.6.1) [13].
We used differentmutation characterisationmethods to analyse the
effect of the 7 ACADS alterations identiﬁed, including PolyPhen-2 [14],
Meta-SNP (including results from other tools: PANTHER, PhD-SNP,
SIFT, and SNAP) [15], PON-P2 [16], PredictSNP (also including re-
sults from MAPP, PhD-SNP, PolyPhen-1, PolyPhen-2, SIFT, SNAP,
nsSNPAnalyzer, and PANTHER) [17], MutPred [18] and MutPred2.
The latter is the latest version of MutPred, which is a joint project
of Dr. Sean Mooney's laboratory at the University of Washington and
Dr. Predrag Radivojac's laboratory at Indiana University and is available
upon request.
3. Results
3.1. Clinical and biochemical data
Wereport the available clinical and biochemical information collected
for each patient from the referring physicians (Table 1). Biochemically,
we report the data on the C4-C measurements on DBS and the subse-
quent EMA values, established before the beginning of the riboﬂavin
therapy. The available C4-C retesting conﬁrmed the data of the ﬁrst
assessments (data not shown).
The age of patients at the time of the study ranged from newborn to
24 years. All patients were born from unrelated parents with the excep-
tion of Pt 4, Pt 8, Pt 9, and Pt 11, who were born from consanguineous
parents.
10 SCADD patients were enrolled through NBS programmes and
their diagnosis was conﬁrmed between 7 and 26 days of age upon de-
tecting elevated plasma C4-c and increased excretion of urinary EMA
(Table 1). None of these patients were found to be carnitine deﬁcient
and the genetic and biochemical metabolic work-up pointed to the
possibility of SCADD. At present, these patients are undergoing riboﬂavin
therapy and they are all still asymptomatic.However, hypotonia was observed at the moment of recall for C4
positive screening between 8 and 16 days of life in Pts, 8, 9 and 11. Preg-
nancy or neonatal complications in these patients were excluded. The
hypotonia improved and completely disappeared after riboﬂavin treat-
ment was established. At present, after an 8 year long follow-up, pa-
tients are asymptomatic. Riboﬂavin treatment has maintained patients'
EMA urinary levels at signiﬁcantly lower values.
Pts 1 and 5 were brought to medical attention, at 5 and 17 years of
age, due to developmental delay and dysmorphic features. Epilepsy, mi-
crocephaly andmaculopathywere also observed in Pt 1. All patients diag-
nosed through NBS began riboﬂavin therapy within 20 days to 2 months
of age. Pt 1 is also being treated with antiepileptic drugs.3.2. ACADS molecular analysis
Of the 13 different genetic alterations identiﬁed, 11 were novel, 7
missense: [c.700CNT (p.Arg234Trp), c.814CNT (p.Arg272Cys),
c.842GNC (p.Gly281Ala), c.869CNG (p.Ala290Gly), c.1054GNA
(p.Ala352Thr), c.1130CNT (p.Pro377Leu), c.1157GNA (p.Arg385His)],
2 nonsense: c.66GNA (p.W22*) and c.531GNA (p.Trp171*), 1 deletion
(c.981_983delGAC) and 1 synonymous [c.765GNT (p.Gly255Gly)].
Among the 7 new missense variants, 5 occurred at new positions
(p.Arg234, p.Gly281, p.Ala290, p.Ala352 and p.Pro377); the remaining
two amino acids (p.Arg272 and p.Arg386) had previously been found
to generate other disease-causing alleles [1]. The homozygous or hetero-
zygous state of the ACADS genetic variants was conﬁrmed by molecular
analysis in all patients' relatives.3.3. In silico structural predictions of new ACADS missense variants
None of the missense variants (p.Arg234Trp, p.Arg272Cys,
p.Gly281Ala, p.Ala290Gly, p.Ala352Thr, p.Pro377Leu and p.Arg386His)
or the synonymous variant (c.765GNT)were found in the Italian control
population. The 1000 Genomes project database does not include the
newly presented variants except for the p.Pro377Leu (MAF = 0.0002).
In the EXAC browser all the new variants identiﬁed were present at
very low frequency (MAF ranging from 0.0008 to 0.002).
We used different mutation characterisationmethods to analyse the
possible association of the 7 genetic alterations here reported with
SCADD.
Most of the tools (e.g., PANTHER, PhD-SNP, SIFT, SNAP, PredictSNP,
PolyPhen-1, PolyPhen-2, MutPred, MutPred2) predict that the 7 muta-
tions are probably disease causing (Fig. 1). A graphical view of the altered
amino acids mapped onto the tridimensional SCAD structure is reported
in Fig. 2.
Structural and functional properties of protein sequences were
analysed byMutPred to predict the actionable molecular mechanism
of disruption due to these amino acid variants on SCAD. These results
suggest that the p.Arg272Cys is very likely to cause loss of a methyl-
ation function, and p.Arg386His is likely to cause loss of protein stabil-
ity. Both cases are considered to be disruptive with a conﬁdent score.
The MutPred results also gave actionable hypotheses of disruptions
for all the 7 mutations, including loss of intrinsic disorder due to
p.Arg234Trp, loss of protein stability due to p.Ala290Gly, and gain of
protein stability and loss of intrinsic disorder because of p.Pro377Leu
(Fig. 2, Table 2).
The results obtained from MutPred2, that considers around 57
structural/functional properties compared to the 14 properties used
by MutPred, indicate that all 7 variants are probably deleterious with
scores above 0.75. The results also show a very conﬁdent hypothesis
that the SCAD protein is very likely to gain a palmitoylation function if
the arginine at position p.272 of SCAD is mutated to cysteine.
Overall, the results from the differentmutation prediction tools sug-
gest that these 7 mutations are likely to be deleterious.
Fig. 1. Results of the predicted effect of themissense mutations identiﬁed using the PredictSNP tools MAPP, PhD-SNP, PolyPhen-1, PolyPhen-2, SIFT, SNAP, nsSNPAnalyzer, and PANTHER.
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(p.Gly255Gly) new synonymous variant
In silico algorithms predicted that the exonic c.765GNT
(p.Gly255Gly) variant would create a new cryptic donor splice site
(Fig. 3). This genetic lesion was identiﬁed at the heterozygous state in
Pt 12 and in his father. Pt 2 and his relatives were analysed by RT-PCR
using an oligonucleotide set designed to discriminate between the wt
ACADS transcript and the aberrant transcript potentially induced by
the silent variant. This analysis produces a 519 bp amplicon correspond-
ing to thewild-type ACADSmRNA in the patient's sample, in his relatives
and in controls, and a 487 bp amplicon, corresponding to an alternative
transcript, detected in the patient's and in his father's samples (Fig. 3).
Sequencing analysis of the ampliﬁed fragments from the patient's sample
reveals the c.765GNT variant in the shorter amplicon and the second
disease causing mutation [c.66GNA (p.W22*)] in the longer fragment,
both at the homozygous state. Detection of both these mRNAs in this
sample ruled out nonsense mediated decay (NMD) pathways, which
could be determined by both variants. The alternative m-RNA resulted
in an aberrant frame shift ending in a premature stop codon (PTC), at
position c.882 of the ACADS cDNA. This mutation can be deﬁned as
p.Gly255Alafs*30 at the protein level.Fig. 2. SCADprotein: tridimensional structure predictions highlighting positions of the newmiss
cgl.ucsf.edu/chimera/).4. Discussion
The clinical spectrum of SCAD deﬁciency is extremely heteroge-
neous [1,9]. Available clinical, biochemical, and molecular data from
our series were analysed for determining whether the genotype had a
substantial role in developing signs and symptoms.
We highlight two main consequences. First, there were clinical
differences between children identiﬁed byNBS compared to those iden-
tiﬁed clinically. The latter exhibited severe clinical symptoms including
developmental delay, dysmorphic features and epilepsy. This ﬁnding is
in keeping with previously reported comparative studies including
patients identiﬁed by NBS and clinically referred patients [19].
All patients in our study exhibited at least one new mutation in the
ACADS gene. We underline that EMA and C4-C levels are altered in all
the here reported patients' samples, both patients with two new muta-
tions (Mut/Mut patients) and patients compound heterozygous for a
new mutation and the common c.625GNA variant (Mut/Var patients),
as also previously reported [1].
Our results indicate that initial C4-C levels cannot differentiate
between Mut/Mut and Mut/Var patients. A correlation between C4-C
levels and genotypes was not found, probably because acylcarnitine
amounts may be sensitive to how long a patient has fasted [9].ensemutations identiﬁed. The graph is generated viaUCSF Chimera package (http://www.
Table 2












c.700CNT (p.Arg234Trp) 0.581 0.838 Loss of disorder




c.842GNC (p.Gly281Ala) 0.979 0.938 –
c.869CNG (p.Ala290Gly) 0.761 0.763 Loss of stability
c.1054GNA (p.Ala352Thr) 0.788 0.876 –
c.1130CNT (p.Pro377Leu) 0.754 0.836 Gain of stability
Loss of disorder
c.1157GNA (p.Arg386His) 0.905 0.917 Loss of stability
⁎ P is the P-value that certain structural and functional properties are impacted.
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depending on genotype. The Mut/Mut patients showed EMA levels far
above 100mmol/mol creatinine, whereas patients compound heterozy-
gous for a new mutation and the common c.625GNA variant (Mut/Var
patients) presented EMA levels below 100 mmol/mol creatinine.
Molecular analyses were performed to deﬁne eventual genotype–
phenotype correlations in our cohort. Only 59 ACADS mutations are
reported to cause SCADD (https://portal.biobase-international.com/
hgmd/), even if the disease has an incidence of 1:35.000–50.000 live
births, and the gene is composed by 10 exons spanning about 14.2 kb,
in keeping with the average length of human genes. We here report
11 new variants, a consistent number of mutations identiﬁed in the
ACADS gene at the present time. Between these variants, three are drastic
changes, two nonsense mutations and one deletion, which clearly give
rise to deleterious effects on the corresponding SCAD proteins.
In silico tools were used to evaluate the potential pathogenic role of
the newly identiﬁedmissense variants. Computational analyses suggest
that the 7 newmissensemutationswe identiﬁed cause abnormal protein
structures and functions of the SCAD enzyme, thereby leading to disease.
In particular, there is a very conﬁdent hypothesis that the p.Arg272CysFig. 3. Splicing alteration causedby the c.765GNT variant detected in Pt 12 at a heterozygous stat
product is underlined. B. Aberrant splicing event, consisting of a 31 nucleotide deletion in exon 6
the aberrant splicing product. The nucleotide change is underlined. C. Normal sequence analys
Pt12 m-RNA analysis.causes the gain of palmitoylation in this position. S-Palmitoylation is a
key regulatorymechanism controlling protein targeting, localisation, sta-
bility, and activity and that the potential loss or gain of palmitoylation
sites are closely associated with human disease [20].
Various studies have addressed the possibility that SCADD could be
monogenic, multifactorial or a benign condition [8–10,19,21]. In partic-
ular, it is doubtful if SCADD is suited for inclusion in NBS programmes
[22].
Based on our data it emerges a secondmain consequence: functional/
structural data can elucidate the role of newmissense variants identiﬁed
in SCADD patients. Molecular data clearly correlate with biochemical
levels of SCADD metabolic biomarkers. Perspective studies with long
term follow-up are needed to carefully monitor the eventual onset of
neurological manifestations in patients detected by NBS programmes,
as previously demonstrated [2]. We emphasise that molecular analysis,
which can identify severe genotypes, can indicate which patients should
unquestionably receive a long term follow-up.
Furthermore, we identiﬁed the ﬁrst synonymous and pathogenic
substitution in the SCAD protein. Nucleotide substitutions in gene
coding regions, which do not alter protein sequence, were traditionally
hypothesised to bear no effect on proteins andwere called silent, a con-
cept that has been overturned in recent years [23]. Synonymous muta-
tions are now widely acknowledged to cause disease in humans and to
have thepotential to inﬂuencemultiple levels of cellular biology [24]. In-
deed, the novel c.765GNT (p.Gly255Gly) synonymous variant generates
a splice junction internal to ACADS exon 6, a drastic change resulting in a
premature stop codon at SCAD level.
5. Conclusions
In the current era of genome wide association and next generation
sequencing projects, our results satisfy the necessity of combining
sequencing analysis with functional–structural predictions to derive
the clinical signiﬁcance of the genetic variants identiﬁed.
We underline that molecular analysis, which also evaluates the role
of uncommon and often uncharacterised variants, along with in silico
functional studies, provides physicians with essential information to
manage patients diagnosed with SCADD.e. A. Correct splicing event. Thewild type nucleotide that is changed in the aberrantm-RNA
, due to an additional donor site. Dotted lines indicate a different coding frame occurring in
is of exon 6 from m-RNA analysis performed in normal controls D. Aberrant splicing from
119R. Tonin et al. / BBA Clinical 5 (2016) 114–119Transparency document
The Transparency document associatedwith this article can be found,
in the online version.
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